Europe Lung Cancer Screening Software Market – Industry Trends and Forecast to 2029

Europe Lung Cancer Screening Software Market Analysis and Size

Control of lung cancer death rates is one of the major concerns for healthcare facilities. Public and private organizations are taking initiatives to launch screening programs to control the death rates. In addition, companies are launching advanced software to ease the management of patients’ data and provide better care with strict data privacy guidelines.

Increase in prevalence of lung cancer, rising awareness among people about lung cancer, increasing government initiatives, and growing number of screening programs are some of the major factors driving the growth of the market. In addition, advancement in Artificial Intelligence (AI)-based solutions and strategic initiatives by key market players are creating opportunities in the field of lung cancer screening software.

However, data privacy issues and lack of unskilled labor are expected to hamper the market growth in the forecast period.

Data Bridge Market Research analyzes that the Europe lung cancer screening software market is expected to reach the value of USD 27,518.34 thousand by 2029, at a CAGR of 19.6% during the forecast period. Cloud based solutions accounts for largest mode of delivery segment in the market. The market report also covers pricing analysis, patent analysis, and technological advancements in depth.

Market Definition

Lung cancer screening is identifying stages of lung cancer using different technologies and software. Lung cancer screening using CT is the most recommended technique for screening lung cancer. The rising use of this technique is expected to accelerate the need for advanced software for lung cancer screening. This software helps to manage patients’ participation in lung screening programs and provides an efficient way for healthcare professionals to collect, curate, and transfer data to clinicians and patients. In addition, this software enables in the identification of patients at risk and automates the flow of data with integrated electronic health records.

Europe Lung Cancer Screening Software Market Dynamics

This section deals with understanding the market drivers, opportunities, restraints and challenges. All of this is discussed in detail below:

Drivers

• Increase in prevalence of lung cancer cases globally

Lung cancer is a leading cause of death in men and women. According to World Cancer Research Fund International, lung cancer is the second most common cancer worldwide. It is the most common cancer in men and second most common in women. There were more than 2.2 thousand new cases of lung cancer in 2020. Increasing prevalence of lung cancer cases creates need to adopt lung cancer screening software for early diagnosis and acts as a driving factor for the market growth.

• Increase in awareness regarding the benefits of early diagnosis and frequent screening

The rising awareness programs of lung cancer by public, non-profit, and private organization are anticipated to boost the market growth. These initiatives aim to prevent diseases, reduce stigma and prejudice, and promote research. The awareness among the population regarding lung cancer has increased. Because there are many awareness programs by different organizations, people know about lung cancer that can be cured if diagnosed early. Thus, raising awareness among populations is driving the market growth.

• Government initiatives were undertaken to implement screening programs for various diseases

The burden of cancer continues to increase globally and has great financial, emotional, and physical stress on health systems, products, families, and individuals. In countries with strong health systems, the survival rate of many types of cancer is improved due to survivorship, quality care, increased awareness, and accessible early detection. Centers for Disease Control and Prevention, U.S., tribes, and the U.S.-Pacific islands and territories through the National Comprehensive Cancer Control Program (NCCCP) are to form or support alliances to combat cancer in their communities. Due to these initiatives, more audiences are educated and more consciously dispersed, pushing the global audience to take further precautions and practice preventive examinations, promoting the market.

• Growing number of screening programs across the globe

Screening is an effective method of detecting early-stage cancer. There is an increasing trend in lung cancer incidences in developing countries. Although there are regular recommendations for screening for breast and cervical cancer, it is not the same in the case of lung cancer. Most countries or institutions have initiated the feasibility and disease screening of Low-Dose Computed Tomography (LDCT) for lung cancer. The increasing number of lung cancer screening has created an opportunity for the market players. Hence, the increasing diagnostic rate acts as a driving factor for market growth.

Opportunity

• Rising collaborations, mergers & acquisitions among the market players

The companies operating in the market are adopting several strategies, including mergers and acquisitions, product launches, agreements, pipeline development, collaborations, and market expansion among others, to boost their business in various dimensions. These strategic decisions by the companies are expected to offer significant opportunities for the market players operating in the market.

Restraint/Challenge

• Issues related to the availability of software

There are certain issues/barriers related to effective and efficient lung cancer screening and the availability of lung cancer screening software in developing nations. Issues are competing demands for time, knowledge about lung cancer screening, evolving attitudes about the effectiveness of screening, nihilism related to historically poor lung cancer treatment outcomes, and limited training and requirement approval for local authorities or country medical device regulatory body. All these issues delay launches and availability of the product. Also, the demand for lung cancer screening software is hampered due to technical issues related to the available software thereby, acting as a restraint for market growth.

Post-COVID-19 Impact on Europe Lung Cancer Screening Software Market

COVID-19 created a major impact on various industries as almost every country opted for the shutdown of every facility except the ones dealing in the essential goods segment. The government took some strict actions such as the shutdown of facilities and sale of non-essential goods, blocking international trade, and many more to prevent the spread of COVID-19. The only business which was running during this pandemic situation was the essential services that were allowed to open and run the processes.

COVID-19 created new and unfamiliar challenges for healthcare providers to deliver patient care. Many non-essential but important services such as lung cancer screening were temporarily suspended to protect the health of staff and patients. Healthcare institutions faced unprecedented challenges regarding scheduling, patient monitoring, and follow-up of patient-service communication to ensure continuity of care during COVID-19 and when services could be continued safely. COVID-19 created new challenges for lung cancer screening programs, in many cases, delaying screening by several months and creating more difficulties for management and scheduling teams. Although the COVID-19 crisis shed new light on the importance of respiratory assistance, it will hopefully have a major impact on reducing stigma of screening for cancer. There are more than 10,000,000 eligible patients in the U.S. who are eligible for lung cancer screening, less than 5 percent of whom are actively enrolled in the screening program. COVID-19 created a negative impact on the market.

However, the lung cancer screening software companies are struggling and continuously taking different strategic decisions to control the situation. The players are involved in strategic activities such as partnerships, collaborations, and mergers & acquisitions among others to improve the technology involved in the market. With this, the companies will bring advanced and accurate solutions to the market. In addition, the government initiatives to boost digitization across industries have also led to market growth.

Recent Developments

• In July 2022, GE Healthcare launched their latest product and most advanced ultrasound, the next-generation Voluson Expert 22. This latest addition to GE Healthcare’s award-winning Women’s Health portfolio utilizes graphic-based beam former technology, which produces higher quality images and offers greater flexibility in imaging functions. With this product, the company made its position much stronger in the area of products and service providers to healthcare institutions.
• In October 2021, Thynk Health announced a partnership with Infervision, to fight lung cancer with the world’s most advanced technologies. It offers an opportunity for lung cancer screening and pulmonary nodule management. With this partnership, the company increased its market presence.

Europe Lung Cancer Screening Software Market Scope

Europe lung cancer screening software market is segmented into eight notable segments based on mode of delivery, product, type, application, platform, purchase mode, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Mode of Delivery

• Cloud Based Solutions
• On-Premise Solutions
• Web Based Solutions

On the basis of mode of delivery, the market is segmented into cloud based solutions, on-premise solutions, and web based solutions.

Product

• Lung Cancer Screening Radiology Solution
•  Lung Cancer Screening Patient Management Software
•  Nodule Management Software
•  Data Collection and Reporting
•  Patient Coordination and Workflow 
•  Lung Nodule Computer Aided Detection
•  Pathology and Cancer Staging
•  Statistical Audit Reporting
•  Screening PACS
•  Practice Management 
•  Audit Log Tracking  

On the basis of product, the market is segmented into lung cancer screening radiology solution, lung cancer screening patient management software, nodule management software, data collection and reporting, patient coordination and workflow, lung nodule computer aided detection, pathology and cancer staging, statistical audit reporting, screening PACS, practice management, and audit log tracking.

Type

• Computer-Assisted Screening
•  Traditional Screening

On the basis of type, the market is segmented into computer-assisted screening and traditional screening.

Application

• Non-Small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer (SCLC)

On the basis of application, the market is segmented into Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

Platform

• Standalone
• Integrated

On the basis of platform, the market is segmented into standalone and integrated.

Purchase Mode

• Institutional
• Individual

On the basis of purchase mode, the market is segmented into individual and institutional.

End User

• Oncology Centers
• Hospitals
• Ambulatory Surgical Centers
• Others

On the basis of end user, the market is segmented into hospitals, oncology centers, ambulatory surgical centers, and others.

By Distribution Channel

• Direct Tender
• Third Party Distributors

On the basis of distribution channel, the market is segmented into direct tender and third party distributors.  

Europe Lung Cancer Screening Software Market Regional Analysis/Insights

The Europe lung cancer screening software market is analyzed and market size insights and trends are provided based on mode of delivery, product, type, application, platform, purchase mode, end user, and distribution channel.as referenced above.

The countries covered in this market report are Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium and rest of Europe. Germany dominates the market as lung cancer is the leading cause of cancer death in Europe which creates a need to adopt lung cancer screening software for early diagnosis. Moreover, the prevailing sophisticated level of healthcare facilities in the European region has also led to the huge growth of market in the region.  

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Europe Lung Cancer Screening Software Market Share Analysis

Europe lung cancer screening software market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.

Some of the major players operating in the market are PenRad Technologies Inc., Koninklijke Philips N.V, Volpara Health Limited, Thynk Health, Nuance Communications, Inc., Siemens Healthcare GmBH, MyCareWare, Inc., MagView, MeVis Medical Solutions AG, Canon Medical Informatics, Inc., General Electric Company, Epic Systems Corporation, Lungview, Eon, Medtronic, Coreline Soft, Co., Ltd., Optellum Ltd, HealthMyne, Oncocyte Corporation, Genesystem, REVEALDX, FUJIFILM Holdings Corporation, F. Hoffmann-La Roche Ltd, Median Technologies, AstraZeneca, and Aidence.com among others.

SKU-55133